Change Order #1 to Master Services Agreement Attachment #1, dated January 3, 2017, by and between Acadia Pharmaceuticals GmbH and Siegfried AG

Contract Categories: Business Operations - Services Agreements
EX-10.2 3 acad-ex10_2.htm EX-10.2 EX-10.2

Exhibit 10.2

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

 

CHANGE ORDER # 1 to MSA Attachment No. 1

[***]

 

This Change Order #1 to MSA Attachment No. 1 (“Change Order”), is effective as of January 3, 2017, and amends certain provisions of the MSA Attachment No. 1 effective December 15, 2016 (the “Original MSA Attachment” and collectively with this Change Order, the “MSA Attachment”), between ACADIA Pharmaceuticals GmbH (“ACADIA”) and Siegfried AG (“SIEGFRIED”). The MSA Attachment is governed by the Master Services Agreement dated December 15, 2016 between ACADIA and SIEGFRIED.

The parties hereby agree as follows:

1.
Except as expressly amended hereby, the Original MSA Attachment shall remain in full force and effect.
2.
The following services will be added to the current scope of services in Section 2.1 of the Original MSA Attachment:
a.
[***] (“Additional Services”).
3.
The total costs [***] are hereby increased by [***] CHF for the Additional Services.

[***]

4.
This Change Order may be executed in counterparts, each of which shall be deemed an original, and which all together with this writing shall be deemed a single, binding document. PDF copies of a counterpart delivered by email shall have the same force and effect as an original signature.

 

Change to Fees and Expenses

How will additional expense be billed?

[***]

Quotation fee due to this Change Order under PO [***]

will be increased by : [***] CHF

[***] This certifies that the authorized signatories below have reviewed and approved the information provided in this Change Order and that SIEGFRIED and ACADIA have agreed to complete the revised scope of work based on the price revisions listed above.

SIEGFRIED AG:

/s/ Dr. Maurits Janssen Head Business Development 1/12/2017

SIEGFRIED Business Manager Title Date

/s/ Anders Sjoberg Project Manager 1/12/2017

SIEGFRIED Project Manager Title Date

 

ACADIA PHARMACEUTICALS GMBH:

 

/s/ Glenn F. Baity Director 1/6/2017

Glenn F. Baity Title Date